Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PROTAGONIST THERAPEUTICS, INC. reported revenue of $46M, down 89.4% year over year. Operating margin was -343.6% and net margin -282.8%, on a free-cash-flow margin of 121.9% with capital expenditure at 3.5% of revenue. Every figure is computed directly from PTGX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $46M | -343.6% | -282.8% |
| FY2024 | $434M | 58.2% | 63.3% |
| FY2023 | $60M | -156.1% | -131.6% |
| FY2022 | $27M | -494.2% | -479.3% |
| FY2021 | $27M | -460.0% | -458.9% |
How does PTGX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.